Upregulated enhancer of rudimentary homolog promotes epithelial‑mesenchymal transition and cancer cell migration in lung adenocarcinoma

Tsai,Ying-Ming; Wu,Kuan-Li; Huang,Yung-Chi; Wu,Yu-Yuan; Chang,Chao-Yuan; Chang,Yung-Yun; Chiang,Hung-Hsing; Liu,Lian-Xiu; Hung,Jen-Yu

doi:10.3892/mmr.2023.13132

Upregulated enhancer of rudimentary homolog promotes epithelial‑mesenchymal transition and cancer cell migration in lung adenocarcinoma

Authors:
- Ying-Ming Tsai
- Kuan-Li Wu
- Yung-Chi Huang
- Yu-Yuan Wu
- Chao-Yuan Chang
- Yung-Yun Chang
- Hung-Hsing Chiang
- Lian-Xiu Liu
- Jen-Yu Hung
View Affiliations

Affiliations: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
Published online on: November 21, 2023 https://doi.org/10.3892/mmr.2023.13132
Article Number: 9
Copyright: © Tsai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is one of the deadliest cancers regarding both mortality rate and number of deaths and warrants greater effort in the development of potential therapeutic targets. The enhancer of rudimentary homolog (ERH) has been implicated in the promotion and progression of certain types of cancer. In the present study, ERH was assessed for its expression pattern and survival association with LUAD in public transcriptomic and proteomic databases. Bioinformatic methods and data from websites, including University of Alabama at Birmingham CANcer data analysis Portal and The Cancer Genome Atlas, were utilized to demonstrate the functional behaviors and corresponding pathways of ERH in LUAD. Human A549 and CL1‑0 cell lines were used to validate the findings via functional assays. It was demonstrated that the expression of ERH, at both the transcriptomic and proteomic levels, was higher in LUAD compared with in adjacent non‑tumor lung tissue and was associated with worse survival prognosis. Moreover, high ERH expression was correlated with more aggressive functional states, such as cell cycle and invasion in LUAD, and the positive ERH‑correlated gene set was associated with worse survival and an immunosuppressive tumor microenvironment. Small nuclear ribonucleoprotein polypeptide G was identified as a molecule that potentially interacted with ERH. Lastly, it was demonstrated that ERH promoted epithelial‑mesenchymal transition and cell migration in vitro, but not proliferation. In conclusion, higher expression of ERH in LUAD may facilitate cancer progression and confer worse outcomes. Further deep investigation into the role of ERH in LUAD is needed.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Skřičková J, Kadlec B, Venclíček O and Merta Z: Lung cancer. Cas Lek Cesk. 157:226–236. 2018.PubMed/NCBI
3	Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, Irving LB and Manser R: Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 8:CD0138292022.PubMed/NCBI
4	Deb D, Moore AC and Roy UB: The 2021 global lung cancer therapy landscape. J Thorac Oncol. 17:931–936. 2022. View Article : Google Scholar : PubMed/NCBI
5	Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, et al: Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. J Clin Oncol. 40:3323–3343. 2022. View Article : Google Scholar : PubMed/NCBI
6	Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, et al: The 2021 WHO classification of lung tumors: Impact of advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
7	Luo YH, Liang KH, Huang HC, Shen CI, Chiang CL, Wang ML, Chiou SH and Chen YM: State-of-the-art molecular oncology of lung cancer in Taiwan. Int J Mol Sci. 23:70372022. View Article : Google Scholar : PubMed/NCBI
8	Isomura M, Okui K, Fujiwara T, Shin S and Nakamura Y: Cloning and mapping of a novel human cDNA homologous to DROER, the enhancer of the Drosophila melanogaster rudimentary gene. Genomics. 32:125–127. 1996. View Article : Google Scholar : PubMed/NCBI
9	Weng MT and Luo J: The enigmatic ERH protein: Its role in cell cycle, RNA splicing and cancer. Protein Cell. 4:807–812. 2013. View Article : Google Scholar : PubMed/NCBI
10	Krzyzanowski MK, Kozlowska E and Kozlowski P: Identification and functional analysis of the erh1(+) gene encoding enhancer of rudimentary homolog from the fission yeast Schizosaccharomyces pombe. PLoS One. 7:e490592012. View Article : Google Scholar : PubMed/NCBI
11	Wang X, Xie H, Zhu Z, Zhang J and Xu C: Molecular basis for the recognition of CIZ1 by ERH. FEBS J. 290:712–723. 2023. View Article : Google Scholar : PubMed/NCBI
12	Fang W and Bartel DP: MicroRNA clustering assists processing of suboptimal MicroRNA hairpins through the action of the ERH protein. Mol Cell. 78:289–302.e6. 2020. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Wang X, Wang H, Jiang Y, Xu Z and Luo L: Elevated small nuclear ribonucleoprotein polypeptide an expression correlated with poor prognosis and immune infiltrates in patients with hepatocellular carcinoma. Front Oncol. 12:8931072022. View Article : Google Scholar : PubMed/NCBI
14	Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, et al: Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci USA. 109:E3659–E3667. 2012. View Article : Google Scholar : PubMed/NCBI
15	Pang K, Zhang Z, Hao L, Shi Z, Chen B, Zang G, Dong Y, Li R, Liu Y, Wang J, et al: The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells. BMC Cancer. 19:2252019. View Article : Google Scholar : PubMed/NCBI
16	Zhang D, Chu YJ, Song KJ, Chen YL, Liu W, Lv T, Wang J, Zhao H, Ren YZ, Xu JX, et al: Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition. Biomed Pharmacother. 125:1099742020. View Article : Google Scholar : PubMed/NCBI
17	Park JH, Park M, Park SY, Lee YJ, Hong SC, Jung EJ, Ju YT, Jeong CY, Kim JY, Ko GH, et al: ERH overexpression is associated with decreased cell migration and invasion and a good prognosis in gastric cancer. Transl Cancer Res. 9:5281–5291. 2020. View Article : Google Scholar : PubMed/NCBI
18	Park C, Lee WS, Go SI, Jeong SH, Yoo J, Cha HJ, Lee YJ, Kim HS, Leem SH, Kim HJ, et al: Apoptotic effects of anthocyanins from vitis coignetiae pulliat are enhanced by augmented enhancer of the rudimentary homolog (ERH) in human gastric carcinoma MKN28 cells. Int J Mol Sci. 22:30302021. View Article : Google Scholar : PubMed/NCBI
19	Pang K, Li ML, Hao L, Shi ZD, Feng H, Chen B, Ma YY, Xu H, Pan D, Chen ZS and Han CH: ERH gene and its role in cancer cells. Front Oncol. 12:9004962022. View Article : Google Scholar : PubMed/NCBI
20	Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lim WK, Wang K, Lefebvre C and Califano A: Comparative analysis of microarray normalization procedures: Effects on reverse engineering gene networks. Bioinformatics. 23:i282–i288. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ghufran SM, Sharma P, Roy B, Jaiswal S, Aftab M, Sengupta S, Ghose S and Biswas S: Transcriptome wide functional analysis of HBx expressing human hepatocytes stimulated with endothelial cell cross-talk. Genomics. 115:1106422023. View Article : Google Scholar : PubMed/NCBI
24	Liu CJ, Hu FF, Xia MX, Han L, Zhang Q and Guo AY: GSCALite: A web server for gene set cancer analysis. Bioinformatics. 34:3771–3772. 2018. View Article : Google Scholar : PubMed/NCBI
25	Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
26	Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48((W1)): W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
27	Saadoun S, Papadopoulos MC, Watanabe H, Yan D, Manley GT and Verkman AS: Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J Cell Sci. 118:5691–5698. 2005. View Article : Google Scholar : PubMed/NCBI
28	Chang WA, Yen MC, Hung JY, Yang CJ, Jian SF, Yeh IJ, Liu KT, Hsu YL and Kuo PL: Investigation of the role of tumor necrosis factor-like weak inducer of apoptosis in non-small cell lung cancer. Oncol Rep. 39:573–581. 2018.PubMed/NCBI
29	Liu CJ, Hu FF, Xie GY, Miao YR, Li XW, Zeng Y and Guo AY: GSCA: An integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 24:bbac5582023. View Article : Google Scholar : PubMed/NCBI
30	Ishikawa K, Ishikawa A, Shoji Y and Imai T: A genotoxic stress-responsive miRNA, miR-574-3p, delays cell growth by suppressing the enhancer of rudimentary homolog gene in vitro. Int J Mol Sci. 15:2971–2990. 2014. View Article : Google Scholar : PubMed/NCBI
31	Fujimura A, Kishimoto H, Yanagisawa J and Kimura K: Enhancer of rudimentary homolog (ERH) plays an essential role in the progression of mitosis by promoting mitotic chromosome alignment. Biochem Biophys Res Commun. 423:588–592. 2012. View Article : Google Scholar : PubMed/NCBI
32	Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
33	Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
34	Mabonga L and Kappo AP: The oncogenic potential of small nuclear ribonucleoprotein polypeptide G: A comprehensive and perspective view. Am J Transl Res. 11:6702–6716. 2019.PubMed/NCBI
35	Bucholc K, Aik WS, Yang XC, Wang K, Zhou ZH, Dadlez M, Marzluff WF, Tong L and Dominski Z: Composition and processing activity of a semi-recombinant holo U7 snRNP. Nucleic Acids Res. 48:1508–1530. 2020. View Article : Google Scholar : PubMed/NCBI